Fwd: Poly-MVA - The First Dietary Supplement To Be Cleared By The FDA For Use In A Cancer Study

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Poly-MVA - The First Dietary Supplement To Be Cleared By The FDA For Use In A Cancer Study
To: mesothelioma77@gmail.com

Main Category: Cancer / Oncology Also Included In: Complementary Medicine / Alternative Medicine Article Date: 15 Jun 2008 - 3:00 PDT CancerAssistanceCenter.org announces the immediate availability of free ...

Sun, 15 Jun 2008 10:00:00 GMT

---

Source: http://www.medicalnewstoday.com/articles/111306.php
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Westville mayor dies after battling lung cancer

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Westville mayor dies after battling lung cancer
To: mesothelioma77@gmail.com

Westville Mayor Michael Galbraith died Friday afternoon an almost four-year bout with lung cancer, according to officials.

Sun, 15 Jun 2008 07:00:00 GMT

---

Source: http://www.courierpostonline.com/apps/pbcs.dll/article?AID=2008806150349
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Practical Prevention: Lower Cancer Risk By Limiting Red Meat

---------- Forwarded message ----------
From: Search for lung cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Practical Prevention: Lower Cancer Risk By Limiting Red Meat
To: mesothelioma77@gmail.com

If you're like most Americans, your daily menu contains a lot of meat. You may have sausage or bacon with breakfast.

Sun, 15 Jun 2008 07:28:48 GMT

---

Source: http://www.kitsapsun.com/news/2008/jun/15/practical-prevention-lower-cancer-risk-by-red/
--
 ~
Powered by RssFwd, a service of Blue Sky Factory, Inc

Fwd: Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Prospective study of bone scintigraphy as a staging investigation for oesophageal carcinoma.
To: mesothelioma77@gmail.com


[1]Br J Surg. 2008 Jun 12; 95(7): 840-844
Jennings NA, Griffin SM, Lamb PJ, Preston S, Richardson D, Karat D, Hayes N

BACKGROUND:: About 10 per cent of patients undergoing radical oesophagectomy for transmural (T3) carcinoma with lymph node involvement (N1) develop symptomatic bone metastases within 12 months of surgery. The aim of this study was to evaluate the introduction of targeted preoperative bone scintigraphy. METHODS:: Of 790 patients with oesophageal carcinoma staged between December 2000 and December 2004, 189 were eligible for potentially curative treatment. (99m)Tc-labelled hydroxymethylene diphosphonate bone scintigraphy was performed in those with stage T3 N1 disease (identified by computed tomography and endoscopic ultrasonography) who were suitable for radical treatment. RESULTS:: A total of 115 patients had bone scintigraphy. The histological diagnosis was adenocarcinoma in 82 patients and squamous cell carcinoma in 33. Bone scintigraphy was normal or showed degenerative changes in 93 patients, and abnormal requiring further investigation in 22. Plain radiography, magnetic resonance imaging and biopsy confirmed the presence of bone metastases in 11 patients (9.6 per cent). CONCLUSION:: Bone is frequently the first site of identifiable distant metastatic spread, and bone scintigraphy is recommended to exclude metastatic disease before radical treatment of advanced oesophageal carcinoma. Copyright (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.



___
Source: http://www.hubmed.org/display.cgi?uids=18551472
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Mutational analysis of genes p14ARF, p15INK4b, p16INK4a, and PTEN in human nervous system tumors.
To: mesothelioma77@gmail.com


[1]Genet Mol Res. 2008; 7(2): 451-9
Almeida LO, Custódio AC, Araújo JJ, Rey JA, Almeida JR, Santos MJ, Clara CA, Casartelli C

Cancer is one of the most common and severe problems in clinical medicine, and nervous system tumors represent about 2% of the types of cancer. The central role of the nervous system in the maintenance of vital activities and the functional consequences of the loss of neurons can explain how severe brain cancers are. The cell cycle is a highly complex process, with a wide number of regulatory proteins involved, and such proteins can suffer alterations that transform normal cells into malignant ones. The INK4 family members (CDK inhibitors) are the cell cycle regulators that block the progression of the cycle through the R point, causing an arrest in G1 stage. The p14ARF (alternative reading frame) gene is a tumor suppressor that inhibits p53 degradation during the progression of the cell cycle. The PTEN gene is related to the induction of growth suppression through cell cycle arrest, to apoptosis and to the inhibition of cell adhesion and migration. The purpose of the present study was to assess the mutational state of the genes p14ARF, p15INK4b, p16INK4a, and PTEN in 64 human nervous system tumor samples. Homozygous deletions were found in exon 2 of the p15INK4b gene and exon 3 of the p16INK4a gene in two schwannomas. Three samples showed a guanine deletion (63 codon) which led to a loss of heterozygosity in the p15 gene, and no alterations could be seen in the PTEN gene. Although the group of patients was heterogeneous, our results are in accordance with other different studies that indicate that homozygous deletion and loss of heterozygosity in the INK4 family members are frequently observed in nervous system tumors.



___
Source: http://www.hubmed.org/display.cgi?uids=18551412
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Bioavailability issues in studying the health effects of plant polyphenolic compounds.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Bioavailability issues in studying the health effects of plant polyphenolic compounds.
To: mesothelioma77@gmail.com


[1]Mol Nutr Food Res. 2008 Jun 12;
Yang CS, Sang S, Lambert JD, Lee MJ

Polyphenolic compounds are common in the diet and have been suggested to have a number of beneficial health effects including prevention of cancer, cardiovascular disease, diabetes, and others. For some dietary polyphenols, certain benficial effects are suggested by epidemiological studies, some are supported by studies in animal models, and still others are extrapolated from studies in vitro. Because of the relatively poor bioavailability of many of these compounds, the molecular basis of these beneficial effects is not clear. In the present review, we discuss the potential health benefits of dietary polyphenols from the point of view of bioavailability. Tea catechins, curcumin, and proanthocyanidins are used as examples to illustrate some of the problems that need to be resolved. Further research on both the biological activity and bioavailability of dietary polyphenols is needed to properly assess their usefulness for the prevention and treatment of disease.



___
Source: http://www.hubmed.org/display.cgi?uids=18551457
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Pregnancy associated breast cancer.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Pregnancy associated breast cancer.
To: mesothelioma77@gmail.com


[1]Eur J Surg Oncol. 2008 Jun 10;
García-Manero M, Royo MP, Espinos J, Pina L, Alcazar JL, López G

BACKGROUND: Breast carcinoma during pregnancy put the health of the mother in conflict with that of the foetus. The aim is to give optimal treatment to the mother to maximise the chances of survival, whilst minimising the risk of harm of the foetus. We report the epidemiology, pathology, clinical picture, therapeutic management and foetal outcome of pregnant women with breast cancer treated in our institution. PATIENTS AND METHODS: Twenty-two pregnant breast cancer patients were treated in our hospital from January 1996 to October 2006. Parents were surveyed by mail or telephone regarding outcomes of children exposed to chemotherapy in uterus. RESULTS: The treatment of breast cancer pregnancy should conform as closely as possible to standardised protocols for patients without concomitant pregnancy. Most of the patients underwent surgery during pregnancy In four cases diagnosed during the first trimester chemotherapy was initiated during the 10th week when organogenesis period was finished. None of the children exposed to chemotherapy during this trimester presented congenital malformations. All 11 cases diagnosed during second and third trimester were treated with Doxorrubicin, Fluoracil and Cyclophosphamide and four cases were treated with taxanes. No congenital malformations were detected. CONCLUSION: Breast cancer can be treated with FAC chemotherapy during the second and third trimesters without significant complications for the children exposed to chemotherapy in uterus. We report four cases treated with taxanes after the first trimester and no congenital anomalies were observed.



___
Source: http://www.hubmed.org/display.cgi?uids=18550321
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: Antrodia camphorata inhibits proliferation of human breast cancer cells in vitro and in vivo.
To: mesothelioma77@gmail.com


[1]Food Chem Toxicol. 2008 May 4;
Hseu YC, Chen SC, Chen HC, Liao JW, Yang HL

Antrodia camphorata (A. camphorata) has been shown to induce apoptosis in cultured human breast cancer cells (MDA-MB-231). In this study, we report the effectiveness of the fermented culture broth of A. camphorata in terms of tumor regression as determined using both in vitro cell culture and in vivo athymic nude mice models of breast cancer. We found that the A. camphorata treatment decreased the proliferation of MDA-MB-231 cells by arresting progression through the G1 phase of the cell cycle. This cell cycle blockade was associated with reductions in cyclin D1, cyclin E, CDK4, cyclin A, and proliferating cell nuclear antigen (PCNA), and increased CDK inhibitor p27/KIP and p21/WAF1 in a dose and time-dependent manner. Furthermore, the A. camphorata treatment was effective in delaying tumor incidence in the nude mice inoculated with MDA-MB-231 cells as well as reducing the tumor burden when compared to controls. A. camphorata treatment also inhibited proliferation (cyclin D1 and PCNA) and induced apoptosis (Bcl-2 and TUNEL) when the tumor tissue sections were examined histologically and immunohistochemically. These results suggest that the A. camphorata treatment induced cell cycle arrest and apoptosis of human breast cancer cells both in vitro and in vivo.



___
Source: http://www.hubmed.org/display.cgi?uids=18550246
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: First synthesis of 3,16,20-polyoxygenated cholestanes, new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sun, Jun 15, 2008 at 11:30 AM
Subject: First synthesis of 3,16,20-polyoxygenated cholestanes, new cytotoxic steroids from the gorgonian Leptogorgia sarmentosa.
To: mesothelioma77@gmail.com


[1]Steroids. 2008 May 3;
Boonananwong S, Kongkathip B, Kongkathip N

Using tigogenin as starting material, (20S)-20-hydroxycholestane-3,6-dione (1), (16S, 20S)-16,20-dihydroxycholestan-3-one (2), (20S)-20-hydroxycholest-1-ene-3,16-dione (3) and (20S)-20-hydroxycholest-4-ene-3,16-dione (4), natural polyoxygenated steroids from the gorgonian, Leptogorgia sarmentosa, were synthesized in four steps. Antitumor activity against three tumor cell lines (breast cancer, MCF7, lung cancer NCI and oral cancer KB) was evaluated. Two compounds (3 and 4) showed strong activity against NCI (IC(50) 6.16 and 10.51muM) and moderate activity against MCF7 and KB, the IC(50) being in the range 30.65-47.22muM. Compound 2 showed moderate activity against NCI (IC(50) 42.68muM) but was inactive against MCF7 and KB whereas compound 1 showed no activity against all tested cells.



___
Source: http://www.hubmed.org/display.cgi?uids=18550136
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc